Critical considerations in pharmacetical bioequivalence testing

Birincil Dil	İngilizce
Bölüm	Makaleler
Yazarlar	Umesh Banakar Bu kişi benim Michael Makoid Bu kişi benim
Yayımlanma Tarihi	30 Mart 2015
Yayımlandığı Sayı	Yıl 1995 Cilt: 11 Sayı: 1-2

APA	Banakar, U., & Makoid, M. (2015). Critical considerations in pharmacetical bioequivalence testing. Marmara Pharmaceutical Journal, 11(1-2), 55-80. https://doi.org/10.12991/mpj.20066
AMA	Banakar U, Makoid M. Critical considerations in pharmacetical bioequivalence testing. mpj. Nisan 2015;11(1-2):55-80. doi:10.12991/mpj.20066
Chicago	Banakar, Umesh, ve Michael Makoid. “Critical Considerations in Pharmacetical Bioequivalence Testing”. Marmara Pharmaceutical Journal 11, sy. 1-2 (Nisan 2015): 55-80. https://doi.org/10.12991/mpj.20066.
EndNote	Banakar U, Makoid M (01 Nisan 2015) Critical considerations in pharmacetical bioequivalence testing. Marmara Pharmaceutical Journal 11 1-2 55–80.
IEEE	U. Banakar ve M. Makoid, “Critical considerations in pharmacetical bioequivalence testing”, mpj, c. 11, sy. 1-2, ss. 55–80, 2015, doi: 10.12991/mpj.20066.
ISNAD	Banakar, Umesh - Makoid, Michael. “Critical Considerations in Pharmacetical Bioequivalence Testing”. Marmara Pharmaceutical Journal 11/1-2 (Nisan 2015), 55-80. https://doi.org/10.12991/mpj.20066.
JAMA	Banakar U, Makoid M. Critical considerations in pharmacetical bioequivalence testing. mpj. 2015;11:55–80.
MLA	Banakar, Umesh ve Michael Makoid. “Critical Considerations in Pharmacetical Bioequivalence Testing”. Marmara Pharmaceutical Journal, c. 11, sy. 1-2, 2015, ss. 55-80, doi:10.12991/mpj.20066.
Vancouver	Banakar U, Makoid M. Critical considerations in pharmacetical bioequivalence testing. mpj. 2015;11(1-2):55-80.